Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Fluconazole + Lacticaseibacillus rhamnosus + Limosilactobacillus reuteri & Vulvovaginal candidiasis (VVC) / Vaginal yeast infection

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Randomized clinical trials (RCTs)

XXX - Fluconazole vs Fluconazole + Lacticaseibacillus rhamnosus GR-1 + Limosilactobacillus reuteri RC-14 & Vulvovaginal candidiasis (VVC) / Vaginal yeast infection
revealed that Lacticaseibacillus rhamnosus GR-1 + Limosilactobacillus reuteri RC-14 can increase the effectiveness of an anti-fungal pharmaceutical agent in curing disease (1).

References

(1) Martinez et al. 2009 Lett Appl Microbiol 48(3): 269-74

see also:
[Antifungals + Probiotics &, Vulvovaginal candidiasis (VVC) / Vaginal yeast infection](brain://mhonNsO4eUGRUsSURyjm9g/Antifunga…

References (Sources)

Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Martinez et al. 2009 Lett Appl Microbiol 48(3): 269-74

AI Chat

7/1/2026

Chat with our artificial intelligence: